{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-024758","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-07-29T13:01:54+00:00","discovered_at":"2026-07-29T13:03:04.293575+00:00","generated_at":"2026-07-29T13:06:41.076748+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF pivotal study","bullets":["Study commenced April 2026; already past midpoint, enrolling at up to 30 sites including outside U.S.","CMO David Kenigsberg cites strong enrollment trajectory reflecting investigator enthusiasm for nPulse technology.","Top-enrolling investigator Frank Cuoco notes minimal learning curve and seamless workflow integration.","Company to provide further commentary on study progress during August 6, 2026 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-024758","json":"https://secwatch.observer/filing/0001437749-26-024758.json","markdown":"https://secwatch.observer/filing/0001437749-26-024758.md","text":"https://secwatch.observer/filing/0001437749-26-024758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/0001437749-26-024758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/plse20260728_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T13:06:41.076748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}